Haemonetics Corporation (HAE) delivered third-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.19, which rose 14.4% year over year. The bottom line was on par with the Zacks Consensus Estimate. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, EPS was 74 cents compared with 61 cents in the prior-year quarter.Following the earnings announcement, shares of HAE rose 0.02% in after-market trading yesterday. HAE’s Q3 RevenuesRevenues increased 2.7% to $348.5 milli ...

Haemonetics Corporation (NYSE:HAE) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities M ...

Haemonetics (HAE) reported $348.54 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 3.7%. EPS of $1.19 for the same period compares to $1.04 a year ago.The reported revenue represents a surprise of -1.30% over the Zacks Consensus Estimate of $353.15 million. With the consensus EPS estimate being $1.19, the company has not delivered EPS surprise.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.09 per share when it actually produced earnings of $1.12, delivering a surprise of 2.75%.Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com | | 3rd Quarter | | 2025 | YTD 2025 | | | --- | --- | --- | --- | --- | --- | | n Revenue, increase | $349 | million, | 4% | $1,030 | million, 7% | | 1 n Organic revenue increase | | —% | | 2% | | | n Earnings per diluted share | | $0.74 | | $2.14 | | | n Adjusted earnings per diluted sha ...

Financial release accessible onlineBOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Tele ...

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, ...

Haemonetics (HAE) recently completed the sale of its whole blood assets to GVS, S.p.A ("GVS"), a leading provider of advanced filtration solutions for highly critical applications. With this development, GVS now has the company’s portfolio of proprietary whole blood collection, processing and filtration solutions, along with its manufacturing facility in Covina, CA and related equipment and assets at its Tijuana, Mexico manufacturing site.The transaction was announced last month and comprises a total cash c ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemone ...